C17 Stock Chart & Stats
€12.40
-€0.38(-6.62%)
At close: 4:00 PM EST
€12.40
-€0.38(-6.62%)
Day’s Range― - ―
52-Week Range€3.16 - €21.70
Previous CloseN/A
Volume0.00
Average Volume (3M)44.00
Market Cap
€1.09B
Enterprise Value€969.82M
Total Cash (Recent Filing)€236.71M
Total Debt (Recent Filing)€834.00K
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Aug 11, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding84,090,420
10 Day Avg. Volume118
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)9.93
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€27.75Price Target Upside123.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance-sheet ScaleVery low debt and an increase in asset/equity scale reduce near-term solvency risk and preserve financial optionality. This durable strength makes future fundraising or partnership financing easier and lowers default risk compared with highly leveraged peers, supporting longer runway.
Positive Phase 1 Soquelitinib DataRobust Phase 1 results with safety, dose-dependent efficacy, durable drug-free remissions and biomarker support materially de-risk a lead program. If replicated in later stages this creates a sustainable clinical asset that can drive partnerships, label expansion and long-term revenue potential.
Governance Support And Board RefreshStrong shareholder approvals, a refreshed board and ratified independent auditor improve governance and oversight. Durable governance strength aids strategic execution, regulatory interactions and credibility with investors and partners when raising capital or negotiating collaborations.
Bears Say
No Revenue; Widening Net LossesAbsence of product revenue and a materially wider trailing loss underscore reliance on development milestones or financing for survival. Over the medium term this elevates dilution and execution risk: continued negative profitability erodes equity unless offset by clinical success or new funding.
High Cash Burn And Negative Free Cash FlowSustained, worsening cash outflows materially shorten the firm's runway and make future capital raises likely. Free cash flow closely tracks net loss, indicating real cash erosion rather than accounting distortions, increasing dilution risk and potentially forcing slower R&D or partner dependence.
Negative ROE And Capital ErosionA negative return on equity signals the company is destroying shareholder capital despite larger asset/equity base. Persistently negative ROE is a structural concern: without commercialization or successful partnering, equity value will be diluted or depleted through repeated financings.
Corvus Pharmaceuticals News
C17 FAQ
What was Corvus Pharmaceuticals Inc.’s price range in the past 12 months?
Corvus Pharmaceuticals Inc. lowest stock price was €3.15 and its highest was €21.70 in the past 12 months.
What is Corvus Pharmaceuticals Inc.’s market cap?
Corvus Pharmaceuticals Inc.’s market cap is €1.09B.
When is Corvus Pharmaceuticals Inc.’s upcoming earnings report date?
Corvus Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.
How were Corvus Pharmaceuticals Inc.’s earnings last quarter?
Corvus Pharmaceuticals Inc. released its earnings results on May 07, 2026. The company reported -€0.132 earnings per share for the quarter, missing the consensus estimate of -€0.125 by -€0.007.
Is Corvus Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc.’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc. pay dividends?
Corvus Pharmaceuticals Inc. does not currently pay dividends.
What is Corvus Pharmaceuticals Inc.’s EPS estimate?
Corvus Pharmaceuticals Inc.’s EPS estimate is -0.14.
How many shares outstanding does Corvus Pharmaceuticals Inc. have?
Corvus Pharmaceuticals Inc. has 84,090,420 shares outstanding.
What happened to Corvus Pharmaceuticals Inc.’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc. reported an EPS of -€0.132 in its last earnings report, missing expectations of -€0.125. Following the earnings report the stock price went down -3.989%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in DE:C17
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€27.75 (123.81% Upside)
€27.75 (123.81% Upside)
Blogger Sentiment
Bullish
DE:C17 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €292.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
273.50%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
325.98%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
C17 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives: robust early efficacy signals (notably cohort 4 AD results), durable responses without rebound, a clean safety profile across >150 patients, supportive biomarker data, favorable PTCL survival metrics versus historical controls, clear plans to expand into multiple indications, and a substantial $189M financing that increases pro forma cash to ~$246M providing runway into Q2 2028. Offsetting factors include materially higher R&D spending, continued quarterly net losses, reliance on small early cohorts pending larger confirmatory trials, timeline uncertainty for registrational data (primary Phase II AD mid-2027; PTCL full readout late 2027), and execution/regulatory risks inherent to multiple concurrent development programs. Overall, the positives (clinical signal, durability, safety, biomarker rationale, and strengthened balance sheet) outweigh the near-term financial and execution challenges, but success depends on upcoming larger trials and interim readouts.View all DE:C17 earnings summariesC17 Stock 12 Month Forecast
Average Price Target
€27.75
▲(123.81% Upside)
Technical Analysis
Options Prices
Currently, No data available
---